Introduction
Several DNA tumor viruses have independently evolved speci®c mechanisms to inhibit tumor suppressor pathways suggesting that these pathways serve a dual purpose in acting as antiviral host cell defenses Neil et al., 1997; Weinberg, 1997; Wold et al., 1994) . This is a dierent view from the suggestion that tumor virus inhibition of tumor suppressor pathways is required to supplement the metabolic needs of the virus in otherwise quiescent cells (Jansen-DuÈ rr, 1996; Moran, 1993) . Host cell defenses to virus infection may include cell cycle shutdown, induction of apoptosis and enhanced immune recognition through upregulation of major histocompatibility complex (MHC) antigens .
The most recently discovered human tumor virus, Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) , was identi®ed in 1994 by representational dierence analysis (Chang et al., 1994) and is etiologically implicated in the development of Kaposi's sarcoma (KS), body cavity-based/primary eusion lymphomas (PEL) and a subset of multicentric Castleman's disease lesions (Cesarman et al., 1995; Chang et al., 1994; Soulier et al., 1995) . The evidence for KSHV infection being a necessary and causal factor for KS is extensive (for reviews, see Oermann, 1996; Olsen and Moore, 1997; Strathdee et al., 1996) . DNA-based and serology-based studies demonstrate a consistent association of this virus with both AIDS-related and AIDS-unrelated forms of KS and the virus is detectable in 90 ± 95% of KS lesions.
Within KS tumors, nearly all tumor cells show evidence of KSHV infection (Bosho et al., 1995; Rainbow et al., 1997; Staskus et al., 1997) . Cellular Xchromosome inactivation studies suggest that KS may have a monoclonal cellular origin (Rabkin et al., 1995; Rabkin et al., 1997) which is supported by preliminary virus terminal repeat analyses (Russo et al., 1996) . However, reasonable disagreement exists as to whether or not KS tumors are composed of fully transformed tumors cells or represent a polyclonal expansion driven by endogenous or exogenous cytokines. In contrast, there is no disagreement that KSHV-associated PEL are of monoclonal cellular origin based on immunoglobulin rearrangement studies (Cesarman et al., 1995) . These lymphomas are frequently coinfected with both KSHV and Epstein-Barr virus (EBV or HHV4) (Cesarman et al., 1995) . Two cell lines (BC-1 and HBL-6) independently derived from the same tumor have the same polymorhpic terminal repeat pattern (Russo et al., 1996) providing strong evidence that KSHV is monoclonal in these tumors as well. Thus, identi®cation of virus-encoded oncogenes may help in understanding the pathogenesis of this lymphoma and provide unique tools for studying cell growth and regulation.
Genomic sequencing of KSHV shows that the virus has a surprising degree of molecular mimicry (piracy) of cellular genes involved in cell replication and growth control (Russo et al., 1996) . KSHV is poorly transmissible in vitro (Foreman et al., 1997; Moore et al., 1996b) and therefore transformation studies require examination of isolated genes. The KSHV genome possesses functional homologs to cellular protoonco-genes (Russo et al., 1996) including a D-type cyclin Godden-Kent et al., 1997; Li et al., 1997) , antiapoptotic bcl-2 (Cheng et al., 1997; and IL-6 homologs (Moore et al., 1996a; Nicholas et al., 1997) , and a constitutively active IL-8-like receptor that induces cell proliferation in rat ®broblasts (Arvanitakis et al., 1997) . KSHV ORF K13 also encodes a protein with motif similarity to virus-encoded FLICE-inhibitory proteins that prevent apoptosis through dominant negative inhibition of the APO-1/CD95 pathway (Bertin et al., 1997; Thome et al., 1997) . These virus genes may directly inhibit cellular responses to infection such as shutdown of cell cycling and induction of apoptosis (Moore et al., 1996a) . EBV, which is closely related to KSHV, induces many of the same cellular regulatory proteins after infection suggesting that both viruses achieve similar alterations in cell signaling and cell cycle regulation, but do so using dierent strategies (Russo et al., 1996) . Many of these viral signaling transduction and regulatory protein homologs are expressed during quiescent (presumably latent) KSHV replication in B cells but are induced to high levels of expression during lytic replication (unpublished data, R Sarid, Y Chang, PS Moore).
Antiviral responses are also initiated or ampli®ed by interferons (IFNs) induced by viral infection. Recent work has demonstrated an important eect of IFN signaling responses on cell growth control (for review, see Taniguchi et al., 1995) which may play a role in either the induction or inhibition of cellular transformation (Harada et al., 1993) . The pleiotrophic activity of IFNs include tumor suppression through induction of the cyclin-dependent protein kinase inhibitor (CDKI) p21 WAF1/CIP1 cell cycle regulatory protein (Chin et al., 1996; Hobeika et al., 1997; Sangfelt et al., 1997) and through induction of apoptosis (Tamura et al., 1995; Tanaka et al., 1996) . Class I IFN (i.e. IFN-a and IFN-b) also induce expression of major histocompatibility complex (MHC) class I antigens which facilitates immune surveillance for infected cells.
KSHV ORF K9 encodes a unique viral protein called vIRF with sequence similarity to the IFN regulatory factor (IRF) protein family (Moore et al., 1996a; Russo et al., 1996) . Members of the IRF family positively or negatively regulate IFN signal transduction through binding to IFN-stimulated response elements (ISRE) in the promoters of genes under IFN induction control . Two members of this family, IRF-1 (Miyamoto et al., 1988) and IRF-2 (Harada et al., 1989) , have antagonistic anti-and pro-oncogenic activities respectively when overexpressed in NIH3T3 cells (Harada et al., 1993) . The 449-amino acid KSHV vIRF has 13% amino acid identity to several IRF members, but lacks the characteristic DNA binding sequence through which IRF proteins recognize speci®c ISRE in the IFN regulated promoters (Moore et al., 1996a) . We show here that vIRF expression inhibits IFN signal transduction in reporter assays, downregulates expression of p21 WAF1/CIP1 and fully transforms NIH3T3 cells. The viral protein appears to provide a unique immune escape mechanism for the virus that may contribute to neoplasia particularly in virusinfected B cells.
Results

Eect of vIRF on IFN reporter assays
To determine whether KSHV vIRF inhibits IFN-b signal transduction as measured by gene expression reporter assays, we transiently cotransfected into HeLa cells a reporter plasmid pH1 containing IFN-b inducible chloramphenicol acetyltransferase (CAT) linked to ISRE elements of the wild-type hamster ISG54 promoter, together with the KSHV ORF K9 cloned into a pMET7 expression vector (pMvIRF), or its reverse construct (pMFRIv). Whereas ISRE-linked CAT activity was inducible with IFN-b in HeLa cells transfected with the reverse construct, CAT induction was nearly completely abolished by increasing doses of the pMvIRF plasmid up to 5 mg ( Figure 1a) . Examination of transfection eciency and protein expression levels (data not shown) indicated that the eect of vIRF was not due to a general inhibition of transcriptional activity. This eect was not cell line speci®c in that vIRF coexpression also inhibited IFNb-induced CAT activity in 293 cells under similar conditions ( Figure 1b ).
DNA-binding and protein interaction studies
No evidence for direct interaction of vIRF with ISRE or known IRF proteins was found under several dierent assay conditions (see Materials and methods). Conditions examined included use of puri®ed bacterial recombinant vIRF protein and nuclear extracts prepared from vIRF-transfected COS7 or NIH3T3 cells in DNA-protein (South-western) assays or electrophoretic mobility shift binding assays (EMSA) with the ISG15 ISRE element. Under these conditions, clear evidence of ISG15 binding to IRF members, such as ISGF3, could be demonstrated. Since vIRF possesses only two of the ®ve conserved amino terminus tryptophans critical for DNA binding motif, it appears unlikely that vIRF inhibits IFN signaling by direct competitive inhibition at the ISRE element. We cannot exclude the possibility that optimized conditions yet to be discovered are required to detect vIRF interactions with ISRE or interferon signaling proteins.
Eect of vIRF on p21 WAF1/CIP1 expression
The IFN-b inducible IRF1 and IRF2 transcriptional regulatory proteins compete for ISRE and have positive and negative IFN regulatory activity respectively. IFN induction of IRF1 may contribute to cell cycle arrest through increased expression of the CDKI p21 WAF1/CIP1 (Hobeika et al., 1997; Sangfelt et al., 1997; Tanaka et al., 1996) . Overexpression of the negative regulator IRF2 can transform NIH3T3 cells, an eect reversed by IRF1 co-overexpression (Harada et al., 1993) , which is consistent with the presumed roles for IRF1 and IRF2 in cell cycle regulation. To examine the eect of vIRF on IFN-inducible gene expression, stable NIH3T3 transfectants expressing vIRF cloned in-frame into a pcDNA3.1/His vector (pcvIRFin) or cloned out-of-frame as a negative control (pcvIRFout) were generated. (Figure 2a and b) . The induction of p21 protein occurring after 500 m IFN-b treatment of the pcvIRFout.1 control cells was completely abolished in all three clones (pcvIRFin.1, pcvIRFin.2, pcvIRFin.3) stably expressing KSHV vIRF in-frame.
NIH3T3 cell transformation studies vIRF inhibits ISRE-containing reporter expression and downregulates p21
WAF1/CIP1 consistent with this protein's putative role in viral immune escape mechanisms. Although no direct vIRF-ISRE binding activity was found, the action of vIRF is functionally similar to that of IRF2. To determine if vIRF, like IRF2, has transformation capacity and can act as an oncogene, in vitro transformation assays were performed on inframe and out-of-frame stable vIRF NIH3T3 transfectant clones.
Three in-frame vIRF NIH3T3 clones lost contact inhibition, had shorter doubling times, grew at higher cell densities and had higher growth rates under low serum conditions than untransfected parental NIH3T3 cells or two NIH3T3 clones transfected with out-offrame vIRF (Figure 3 and Table 1 ). Colony forming WAF1/CIP1 expression measured by immunoblotting eciency in soft agar was 17 ± 41-fold higher for the three pcvIRFin cell clones than the pcvIRFout cell clones or untransfected control cells (Figure 4 and Table 1 ).
Stable vIRF expression in NIH3T3 cells readily resulted in tumor formation after infection into nude mice, whereas no tumor formation occurred after injection of either parental or out-of-frame vIRF expressing NIH3T3 (Table 1) . Each cell line was injected into both¯anks of four nude mice, which were observed until tumor formation or up to 70 days. The three pcvIRFin clones generated tumors at 23 of 24 sites while none of 24 sites injected with the two pcvIRFout cell clones or parental NIH3T3 cells developed tumors after 70 days of observation. The latency of tumor formation was typically short (5 ± 28 days, average 17 days). Tumors had typical histologic features of ®brosarcomas ( Figure 5 ) and were positive for vIRF expression on Northern blotting (not shown).
Discussion
vIRF is the ®rst KSHV-encoded protein found to transform NIH3T3 cells and induce tumor formation. (Moore et al., 1996a) . The mechanism by which vIRF antagonizes IFN-b signaling as measured by our reporter assay is unknown; we found no direct evidence for either ISRE-binding or protein-protein interactions with known IRF family members. It remains possible that optimized conditions may reveal direct vIRF-ISRE or vIRF-IRF interactions although this was examined in our study using a variety of methods. It appears unlikely that vIRF inhibition of IFN-b signaling results from competitive inhibition at the ISRE since the DNA binding regions of vIRF is poorly conserved (Moore et al., 1996a) . Nonetheless, the functional activity of vIRF appears to be similar to IRF2 which acts as a negative regulator of IFN signal transduction by competitive inhibition with IRF1 at ISRE sequences (Harada et al., 1989) .
The eect of vIRF on IFN signal transduction may have a functional eect on cell cycle regulation as well. Cyclin-dependent kinase inhibitior p21 WAF1/CIP1 levels did not increase in NIH3T3 cells expressing vIRF in response to IFN-b treatment although the increase seen in our control cells lines was relatively modest. Hobeika et al. (1997) found similar levels (approximately twofold) of p21 WAF1/CIP1 induction in DU145 prostatic carcinoma cells after treatment with 2500 units IFN-a. This level of p21 WAF1/CIP1 induction correlated with cell cycle arrest in DU145, suggesting that the level of p21 WAF1/CIP1 inhibition found in our study may also contribute the dysregulated growth control of the pcvIRFin NIH3T3 clones. Similar (threefold) levels of p21 WAF1/CIP1 induction by IFN-a were found for Daudi cells by Sangfelt and colleagues while higher levels of induction were found in other cell lines (Sangfelt et al., 1997) . While the eect of vIRF expression on other cell growth control regulation pathways requires further investigation, vIRF inhibition of the IFN-inducibility of p21 WAF1/CIP1 provides in situ evidence that this viral protein can inhibit intracellular IFN signaling.
By inhibiting p21
expression, vIRF may allow KSHV-infected cells to escape cell cycle shutdown initiated as an antiviral response by IFN. It is possible that vIRF expression may also inhibit immune responses against infected cells. NIH3T3 clones stably expressing vIRF had lower baseline levels of major histocompatibility (MHC) class I surface antigen expression than out-of-frame controls (data not shown); however, these cells show poor MHC class I induction after IFN-b treatment and thus the eect of vIRF on IFN-inducibility of MHC class I antigen could not be determined.
A by-product of this survival mechanism may be dysregulated cell proliferation contributing to the transformed phenotype of infected B cells. While KSHV is evolutionarily distant from most other human tumor viruses (with the exception of EBV), it appears to share with other transforming viruses such as adenovirus and papillomavirus the functional capacity to alter retinoblastoma protein-mediated control checkpoints and apoptosis mediated through both p53-dependent and independent pathways . Further, the adenoviral E1a oncoprotein may induce resistance to IFN signaling (Reich et al., 1988) by inhibitory binding to the p300/ CBP transcriptional adaptor protein (Bhattacharya et al., 1996; Zhang et al., 1996) , and downregulation of MHC processing (Rotem-Yehudar et al., 1996) , an analogous eect to that seen in our study of KSHV vIRF.
The convergent evolution of tumor suppressor inhibition by distantly-related tumor viruses suggests that tumor suppressor pathways also serve to control viral infection. The activation of tumor suppressor pathways by interferons, which are antiviral cytokines induced by viral infection, provides additional support to the notion that these pathways serve important antiviral functions. Thus, the speci®c inhibition of tumor suppressor pathways by KSHV-encoded genes leading to cell transformation may be an unintended consequence of this virus' strategy to overcome host cell defense pathways (Moore et al., 1996a; Moore and Chang, 1997) . While vIRF is the ®rst KSHV-encoded protein found to have transforming activity in vitro, other viral gene products, such as v-cyc and v-IL6 are also likely to contribute to KSHV-mediated dysregulation of cell growth control in vivo. Our current study con®rms that interferon signaling pathway activation plays an important role in tumor suppression and that tumor suppressor pathways are likely to have dual roles as antiviral pathways. 
Materials and methods
Cell lines
Expression vectors
A 1368 bp vIRF PCR product generated with the primer set 5'-AAA GAA TTC ATG GAC CCA GGC CAA A-GA CC-3' and 5'-GGG GTC GAG TTA TTG CAT GGC ATC CCA TA-3' was cloned in-frame (pcvIRFin) and outof-frame (pcvIRFout) into the BamHI and EcoRI sites of pcDNA3.1/His, a CMV promoter driven mammalian expression vector (Invitrogen, Carlsbad, CA). pMvIRF and pMFRIv are vIRF and its reverse sequence cloned into the Klenow blunted SacI site of pMET7 mammalian expression vector (a gift of Dr J Culpepper) (Takebe et al., 1988) after excising the vIRF insert from pcvIRF with BamHI and EcoRI then blunting with Klenow fragment. pTvIRFin and pTvIRFout are in-frame and out-of-frame vIRF cloned into the BamHI and XhoI sites of pTrcHis prokaryote expression vector (Invitrogen) after isolation of the vIRF insert from pcvIRFin using the same restriction enzymes. The sequence ®delity of all constructs was veri®ed by bidirectional sequencing on an ABI 377 sequenator (Applied Bio-systems Inc., Foster City, CA). pH1 is a CAT reporter plasmid containing the hamster ISG54 promoter (Bluyssen et al., 1993) with an IFN-b responsive ISRE sequence (a gift from Dr D Levy). PSV is a CMV promoter-driven b-galactosidase expression vector used for determining transfection eciency (Stratagene, La Jolla, CA).
Transfection
CAT cotransfection experiments were performed in 35 mm well tissue culture plates using standard calcium-phosphate method (Fujita et al., 1985) with 0.5 mg of pH1 reporter plasmid DNA and 0.5 mg to 5 mg of plasmid DNA of pMvIRF or pMFRIv. Transfection eciency was standardized by cotransfection of 0.3 mg of PSV DNA. Total amounts of DNA was equalized by addition of salmon sperm carrier DNA. One day after transfection, cells were treated with 500 units per ml of human recombinant IFN-b (Sigma Biosciences, St Louis, MO) for 16 h and harvested for CAT determinations (Harada et al., 1989) . Cell extracts for the CAT assay were standardized according to the transfection eciency as measured by b-galactosidase production.
Generation of vIRF stable cell lines
NIH3T3 cells were transfected with 3 mg of pcvIRFin or pcvIRFout linearized with ScaI (Fujita et al., 1985) . The transfected cells were then selected in medium containing G418 (700 mg per ml), and resistant colonies were isolated after 2 ± 3 weeks. The stable transfectant colonies were further cloned by end-point limiting dilution.
Electrophoretic mobility shift assays (EMSA)
vIRF bacterial recombinant proteins (generated with pTvIRFin or control pTvIRFout using the Xpress protein expression system (Invitrogen)) or whole extracts (Schindler et al., 1992) of pMvIRF or control pMFRIv transiently-transfected COS7 cells were used in EMSA (Hassanain et al., 1993) . DNA probes used contained either the CAG TTT CGG TTT CCC sequence of the ISRE site (Levy et al., 1989) or the CTT TCA GTT TCA TAT TAC TCT AAA TCC AT sequence of the GAS site (Silvennoinen et al., 1993) . vIRF interaction with other cellular factors was assayed using 1 mg of bacterial recombinant vIRF protein or COS7 cell preparations with IFN-b treated WI38 (for ISRE probe EMSA) or IL-6 treated HEPG2 (for GAS probe EMSA) cell nuclear extracts. The authors thank C Schindler and C Lee for assistance with these experiments.
Protein analysis
Immuno-blotting was performed as previously described (Gao et al., 1996) using antibody to p21 WAF1/CIP1 (Calbiochem, Cambridge, MA) and developed with enhanced chemiluminescence (ECL) kit (Amersham Life Science, Arlington Heights, IL). For each determination, 100 mg of total cell protein was loaded per lane and con®rmed by Coomassie Brilliant Blue R-250 staining.
Cell-proliferation assays
Cells were seeded in DMEM supplemented with 10% FBS at 2610 4 cells per 35 mm dishes and media was changed every 3 days. Doubling time was determined by counting cells every 2 days and calculating the growth rate for exponentially growing cells. Saturation density was determined by counting the numbers of cells in culture 3 ± 4 days after reaching con¯uency. For growth in low serum media, cells were grown in DMEM supplemented with 1% FBS and cell numbers were determined daily. All the above experiments were repeated at least three times with six replicates in each determination. Results are the average of the experiments with standard deviations.
Soft-agar assay
Cells (1610 4 ) were suspended in a 0.35% agar solution in DMEM supplemented with 10% FBS, and overlaid onto a 0.5% agar solution in DMEM containing 10% FBS in 35 mm plates prepared 1 day before and incubated in a 37% and 5% CO 2 incubator. One day after incubation, 2 ml of DMEM supplemented with 10% FBS was added. Cells grown in soft agar were counted 12 days after plating. Cloning eciency is the number of colonies6100 divided by the numbers of cells plated. Each determination is the average of three experiments with standard deviations.
Nude mice assay
Cells (1610 6 ) suspended in 100 ml PBS were injected subcutaneously into both¯anks of 4 ± 6 week old nude mice. Mice were checked daily for tumor formation for at least 70 days. Latency was the time required to produce visible tumors. Nude mice experiments were approved by the Ethics Committee of the Institute of Cancer Research and the Home Oce of the UK.
Transcript analysis
Northern blotting was performed under standard conditions with random-labeled probes derived from gel puri®ed, BamHI and EcoRI digested, pcvIRFin vIRF insert.
